This landscape report maps 569 early-stage companies building AI and machine learning into the core of biotech — spanning drug discovery, clinical diagnostics, digital health platforms, and the tools infrastructure powering all of it. This isn’t a narrow slice of computational chemistry companies. It’s the full picture of where AI is embedding itself across the life sciences value chain.

The capital tells the story. Since December 2025, companies in this landscape have generated over $8 billion in aggregate deal value through mega-partnerships with Lilly, Takeda, Novartis, and Bayer. Two AI-native biotechs — Generate Biomedicines and Insilico Medicine — went public, raising nearly $700 million combined. And in what may be the most telling signal of all, Anthropic acquired Coefficient Bio for ~$400 million — an AI foundation model company buying a biotech company, not the other way around.

Small molecules still dominate with 179 companies (31% of the landscape), but the fastest-growing segments — AI-designed antibodies, RNA therapeutics, and macrocyclic peptides — signal a shift toward biological complexity. Pharma isn’t licensing AI for docking simulations anymore. They’re licensing AI for protein design, condensate biology, and modalities that were computationally intractable five years ago.